Background/Aim: Tumors exhibiting constitutively activated PI (3) K/Akt/mTOR signaling are
hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being …

Several studies have established a link between aberrant PI(3)K–Akt–mTOR- and Ras–Raf–MEK–Erk1/2
signaling and neuroendocrine tumor disease. In this study, we comparatively …

Interferon-α (IFN-α) is used for biotherapy of neuroendocrine carcinomas. The interferon-λs (IL-28A/B
and IL-29) are a novel group of interferons. In this study, we investigated the effects …

Background and aims: Inhibition of Wnt/β-catenin signaling by specific inhibitors is currently
being investigated as an antitumoral strategy for various cancers. The role of Wnt/β-catenin …

Peptide receptor radionuclide therapy in advanced neuroendocrine tumors (NETs) demonstrates
a limited objective response rate. The therapeutic efficacy might be further increased …

There are no officially approved therapies for metastatic pheochromocytomas apart from
ultratrace 131 I-metaiodbenzylguanidine therapy, which is approved only in the United States. …

IFN-α is commonly used for biotherapy of neuroendocrine carcinomas. However, its
antitumor efficacy is often limited due to IFN resistance. In this study, we evaluate the role of …

Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1
inhibitor everolimus has been approved for the treatment of advanced NETs. However, …

Metformin is a widely used oral antidiabetic drug with good tolerability. Recent studies
suggest that it also possesses adjuvant potent anticancer properties in a variety of tumors. …

Background/Aims: The tumor suppressor p53 is depleted in many tumor cells by the E3
ubiquitin ligase mouse double minute 2 homolog (MDM2) through MDM2/p53 interaction. A …